Literature DB >> 25185242

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P Fenaux1, D Haase2, G F Sanz3, V Santini4, C Buske5.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25185242     DOI： 10.1093/annonc/mdu180

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  30 in total

1.  Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab.

Authors:  Catherine Lai; Vishal Ranpura; Colin Wu; Matthew J Olnes; Ankur R Parikh; Aarthi Shenoy; Julie Thompson; Barbara Weinstein; Phillip Scheinberg; A John Barrett; Ronan Desmond; Neal S Young; Christopher S Hourigan
Journal:  Blood Adv       Date:  2019-04-09

2.  Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.

Authors:  Sonja Burgstaller; Petra Wiesinger; Reinhard Stauder
Journal:  Drugs Aging       Date:  2015-11       Impact factor: 3.923

3.  Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report.

Authors:  Maria Helena Ornellas; Monique De França Silva; Cristiana Solza; Stella Beatriz Sampaio De Lucena Gonçalves; Liliane Silva De Almeida; Jackline De Paula Ayres-Silva; Taís Leite Seixas; Elenice Ferreira Bastos; Thomas Liehr; Gilda Alves
Journal:  Mol Clin Oncol       Date:  2016-07-01

4.  A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.

Authors:  Vasiliki Pappa; Achilles Anagnostopoulos; Eleni Bouronikou; Evangelos Briasoulis; Ioannis Kotsianidis; Maria Pagoni; Panagiotis Zikos; Konstantinos Tsionos; Nora Viniou; John Meletis; Helen Papadaki; Anna Kioumi; Athanasios Galanopoulos; Elisavet-Christine Vervessou; Elias Poulakidas; Panagiotis Karmas; Kiki Karvounis; Argiris Symeonidis
Journal:  Int J Hematol       Date:  2016-11-04       Impact factor: 2.490

5.  Screening of mutations in the additional sex combs like 1, transcriptional regulator, tumor protein p53, and KRAS proto-oncogene, GTPase/NRAS proto-oncogene, GTPase genes of patients with myelodysplastic syndrome.

Authors:  Carolina Leite; Lucas Delmonico; Gilda Alves; Romario José Gomes; Mariana Rodrigues Martino; Aline Rodrigues da Silva; Aline Dos Santos Moreira; Maria Christina Maioli; Luciano Rios Scherrer; Elenice Ferreira Bastos; Roberto Irineu; Maria Helena Ornellas
Journal:  Biomed Rep       Date:  2017-08-09

Review 6.  Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.

Authors:  Roberto Castelli; Riccardo Schiavon; Valentina Rossi; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2018-04-19       Impact factor: 3.064

Review 7.  Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

8.  Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.

Authors:  Thamer Sliwa; Christine Beham-Schmid; Sonja Burgstaller; Veronika Buxhofer-Ausch; Günther Gastl; Klaus Geissler; Maria Krauth; Peter Krippl; Alois Lang; Andreas Petzer; Stefan Wöhrer; Albert Wölfler; Heinz Gisslinger
Journal:  Wien Klin Wochenschr       Date:  2016-12-13       Impact factor: 1.704

9.  Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.

Authors:  Qiu-Sha Huang; Jing-Zhi Wang; Ya-Zhen Qin; Qiao-Zhu Zeng; Qian Jiang; Hao Jiang; Jin Lu; Hui-Xin Liu; Yi Liu; Jing-Bo Wang; Li Su; Hong-Yu Zhang; Zhen-Ling Li; Su-Jun Gao; Bo Huang; Yu-Ying Liu; Yan-Rong Liu; Lan-Ping Xu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Blood Adv       Date:  2019-11-12

10.  Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Authors:  A Toma; O Kosmider; S Chevret; J Delaunay; A Stamatoullas; C Rose; O Beyne-Rauzy; A Banos; A Guerci-Bresler; S Wickenhauser; D Caillot; K Laribi; B De Renzis; D Bordessoule; C Gardin; B Slama; L Sanhes; B Gruson; P Cony-Makhoul; B Chouffi; C Salanoubat; R Benramdane; L Legros; E Wattel; G Tertian; K Bouabdallah; F Guilhot; A L Taksin; S Cheze; K Maloum; S Nimuboma; C Soussain; F Isnard; E Gyan; R Petit; J Lejeune; V Sardnal; A Renneville; C Preudhomme; M Fontenay; P Fenaux; F Dreyfus
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.